New U.S. Patent Grant to Foamix for Its Hygroscopic and Waterless Breakable Foam Technology

The patent describes unique pharmaceutical foams and their use to deliver a wide range of active agents to treat skin and body cavity conditions.

Rehovot, Israel, May 21, 2010 --( Foamix Ltd., today announced that the United States Patent Office has granted the company a new patent on its Hygroscopic and Waterless Breakable Foam technology platform.

United States Patent No. 7,704,518, entitled “Foamable vehicle and pharmaceutical compositions thereof” claims carriers based on polyol or polyethylene glycol polar solvents, and pharmaceutical compositions and methods of treatment with a wide variety of active agents, which can be delivered to a multiplicity of sites, including skin and various body cavities, such as the vagina.

The waterless foam vehicle can be used to increase the concentration of soluble active agents, thus facilitating enhanced skin penetration of the active agent and thereby augmenting their bioavailability and dermal delivery. This technology platform can also be used for delivering drugs which are sensitive to water. In some cases, such as with non-water-sensitive ingredients, the carriers and pharmaceutical compositions may comprise up to about 10% of water.

"We are pleased to receive this new patent, which covers our unique hygroscopic and waterless foam technology platform. This patent is the eighth issued US patent in our patent estate covering our multiple technology platforms. It strengthens and expands Foamix’s intellectual property position and provides protection for innovative products in our pipeline,” said Dr. Dov Tamarkin, CEO of Foamix.

The granted claims are directed to hygroscopic and waterless foamable carriers and foams based on polyol or polyethylene glycol polar solvents, as well as pharmaceutical compositions that contain a variety of drugs, including antibacterial agents, antifungals, antiviral agents, antiparasitic agents, keratolytic agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-allergic agents, anticancer agents, local anesthetics, retinoids, photodynamic therapy agents, anti-wrinkle agents, skin whitening agents, immunosuppressants and immunomodulators.

About Foamix Ltd.

Headquartered in Rehovot, Israel, Foamix is a leading developer of topical foam and OilGel™ formulations, which can be used for dermatological, gynecological and ophthalmic applications. Foamix’s state-of-the-art foams and OilGel™ formulations provide controlled delivery of a variety of active ingredients. Foamix collaborates with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation.

To date, Foamix has twenty three issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company further has over 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.

For additional information please see:

For more information, please contact:
Dov Tamarkin, Foamix Ltd, +972-8-9316233 or

Foamix Ltd
Dov Tamarkin